Solid Biosciences Inc. announced a non-exclusive worldwide license and collaboration agreement with Andelyn Biosciences for the use of Solid's proprietary next-generation capsid, AAV-SLB101. Under the agreement, Andelyn Biosciences will be able to provide its gene therapy clients with access to AAV-SLB101 in combination with its AAV Curator® Platform, which is designed to optimize gene therapy manufacturing processes. Financial terms of the agreement were not disclosed. Solid Biosciences has over 30 agreements in place for the use of AAV-SLB101.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Solid Biosciences Inc. published the original content used to generate this news brief on November 17, 2025, and is solely responsible for the information contained therein.